Pemvidutide

Pemvidutide, developed under the code name ALT-801 by Altimmune, is a synthetic 29-amino-acid peptide designed to activate two receptors at once: the GLP-1 receptor and the glucagon receptor. Its distinguishing design choice is the ratio between those two activities. Where other dual agonists lean more heavily on one receptor, pemvidutide was engineered for an approximately balanced 1:1 GLP-1/glucagon potency ratio, a decision the developers tie directly to its target indications in the liver.

Structurally, pemvidutide belongs to the oxyntomodulin-like family of glucagon/GLP-1 hybrid peptides. Native peptides of this kind are cleared within minutes, so the molecule carries several stabilizing modifications: an Aib substitution near the N-terminus to block dipeptidyl peptidase-4 cleavage, an intramolecular lactam bridge that locks the helical conformation, and a proprietary lipid-glucuronide side chain (the EuPort domain) that promotes reversible albumin binding. Together these changes support once-weekly subcutaneous dosing without the stepwise dose escalation used with most incretin drugs.

The development program has been unusual in that it has pursued liver disease and obesity in parallel rather than sequentially. Pemvidutide has been studied in people with overweight or obesity, in people with metabolic dysfunction-associated steatotic liver disease (MASLD), in biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) with F2 to F3 fibrosis, and more recently in alcohol use disorder and alcohol-associated liver disease.

It is important to be precise about what pemvidutide is not. It is not an approved medicine. It is not available by prescription in the United States, the European Union or elsewhere, and it is not a dietary supplement or a cosmetic ingredient. Readers who want the broader context on where this class sits can see our overview of next-generation incretin peptides. This article is for educational purposes only and does not replace advice from a qualified healthcare professional.

The two arms of the molecule do different jobs. GLP-1 receptor agonism is the familiar part: it slows gastric emptying, enhances glucose-dependent insulin secretion and acts on hypothalamic and brainstem circuits to reduce appetite and food intake. That is the mechanism behind the weight loss seen with single-agonist drugs such as semaglutide.

The glucagon receptor arm is the part that makes this class interesting for the liver, and also the part that requires the most care. Glucagon receptors are densely expressed on hepatocytes. Their activation increases hepatic fatty acid oxidation, reduces de novo lipogenesis and raises whole-body energy expenditure. In animal and human studies of this class, glucagon agonism is associated with reductions in hepatic lipid content and in circulating cholesterol and triglycerides. The trade-off is that glucagon also drives hepatic glucose output, which is why glucagon-containing agonists have to be balanced carefully enough that the GLP-1 arm offsets any tendency toward hyperglycemia.

The stated rationale for a 1:1 ratio is that it delivers enough glucagon signaling to act directly on the liver while keeping GLP-1 activity sufficient to control appetite and glycemia. A secondary hypothesis, promoted by the developers, is that the increased energy expenditure contributed by glucagon allows a greater share of total weight loss to come from fat rather than lean tissue. That hypothesis is biologically plausible but, as discussed below, it has not been confirmed by a head-to-head trial.

Preclinical work supports the liver-directed logic. In a biopsy-confirmed, diet-induced obese mouse model of steatohepatitis, male C57BL/6J mice fed the AMLN diet for 32 weeks received ALT-801, semaglutide, elafibranor or vehicle daily for 12 weeks. The study compared the pharmacodynamic profile of the dual agonist directly against a GLP-1 single agonist and a PPAR agonist in the same model. Animal models of steatohepatitis replicate human disease only partially, so these results set up a hypothesis rather than establishing a clinical effect.

MOMENTUM was the phase 2 obesity trial of pemvidutide. It enrolled 391 participants with obesity, or with overweight plus at least one weight-related comorbidity, and excluded people with diabetes. Participants were randomized to one of three weekly subcutaneous doses (1.2 mg, 1.8 mg or 2.4 mg, administered without titration) or to placebo, for 48 weeks, alongside diet and exercise guidance.

According to the sponsor's week 48 results, mean weight loss was 10.3%, 11.2% and 15.6% on the 1.2 mg, 1.8 mg and 2.4 mg doses respectively, versus 2.2% with placebo. The company also reported that the weight loss curve on the highest dose had not flattened by the end of treatment, which suggests the 48-week figure may understate what a longer exposure would produce. Trial completion was reported at 74.1% in the pemvidutide groups versus 61.9% on placebo.

Two caveats matter for how much weight to place on these numbers. First, they are company-reported topline and conference data (presented at the American Diabetes Association's 84th Scientific Sessions in 2024), not a peer-reviewed primary publication with full methods, confidence intervals and prespecified analysis populations available for independent scrutiny. Second, this was a phase 2 trial in a selected population without diabetes, so the results do not predict performance in broader groups or against active comparators.

For reference, published trials of approved incretin drugs report mean weight loss in the region of 15% to 17% for semaglutide 2.4 mg and around 20% or more for the highest doses of tirzepatide, in trials of differing design and duration. Cross-trial comparison is unreliable, and the absence of head-to-head data means pemvidutide cannot be ranked against those agents on weight loss alone.

No dosing information in this article should be read as guidance. The doses listed are those administered in a controlled research setting to monitored participants.

The lean mass claim is the single most-repeated statement about pemvidutide, so it deserves a careful reading. The sponsor's body composition analysis from MOMENTUM reported that 21.9% of the weight lost was lean mass and 78.1% was fat mass, measured by dual-energy X-ray absorptiometry (DXA). Company communications contrast this with the framing that lean tissue has accounted for as much as 40% of total weight loss in some datasets involving other incretin drugs.

What this evidence does support: in this trial, in this population, DXA showed that the majority of tissue lost was fat, and the proportion of lean tissue lost was at the favorable end of what has been reported in the weight loss literature. That is a genuinely interesting signal and consistent with the glucagon-driven energy expenditure hypothesis.

What it does not establish is more extensive. There is no head-to-head trial comparing pemvidutide with semaglutide or tirzepatide on body composition, so the comparison with the 40% figure places numbers from different trials, populations, imaging protocols and degrees of total weight loss side by side. The fraction of weight lost as lean mass also varies predictably with how much total weight is lost, with baseline body composition, with age and with protein intake and resistance training during the intervention, none of which is matched across trials. DXA lean mass is not the same thing as skeletal muscle: it includes water, connective tissue and organ mass, and it can shift with hydration status. Finally, no muscle strength, grip strength or physical function endpoints have been reported, so the clinical meaning of the difference remains unknown.

The honest summary is that lean mass preservation with pemvidutide is a promising but unverified comparative claim, currently resting on a sponsor analysis presented at a conference. Confirming it would require a randomized trial with an active comparator, prespecified body composition endpoints and functional outcomes. Until then, treat the marketing shorthand of class-leading muscle preservation as an unproven hypothesis.

IMPACT is the pivotal phase 2b trial in biopsy-confirmed MASH with stage F2 to F3 fibrosis. The 24-week results were published in The Lancet in November 2025, which makes this the most robust peer-reviewed dataset on the molecule to date. Participants received weekly subcutaneous pemvidutide at 1.2 mg or 1.8 mg, again without dose titration, or placebo.

On the primary histological endpoint, MASH resolution without worsening of fibrosis at 24 weeks was achieved by 59.1% of participants on 1.2 mg and 52.1% on 1.8 mg, versus 19.1% on placebo, with p less than 0.0001 for both doses in the intention-to-treat analysis. The second histological endpoint, fibrosis improvement without worsening of MASH, reached 31.8% and 34.5% versus 25.9% on placebo, a difference that was not statistically significant at 24 weeks. That distinction is important: resolution of steatohepatitis and regression of fibrosis are different outcomes, and fibrosis typically responds more slowly.

Supporting measures moved in the same direction. Liver fat on MRI-PDFF fell by 58.0% and 62.8% in relative terms versus 16.2% with placebo. ALT fell by 34.6 and 34.4 IU/L versus 10.3 IU/L on placebo. Systolic blood pressure decreased by roughly 4 to 5 mmHg, lipid parameters improved, and fasting glucose and HbA1c showed no significant change, which addresses the theoretical concern that glucagon agonism might worsen glycemia.

Follow-up data from the 48-week portion of IMPACT were presented at EASL 2026 and reported continued metabolic improvement, including weight loss of 7.5% on the 1.8 mg dose with no apparent plateau, further reductions in waist circumference, triglycerides and total cholesterol, and composite non-invasive fibrosis responses favoring pemvidutide. These later data are conference-stage and should be read as preliminary until published in full.

Note also that the MASH doses studied (1.2 mg and 1.8 mg) are lower than the highest obesity dose, reflecting a program aiming for liver benefit at a weight loss intensity appropriate for liver patients rather than maximal weight reduction.

Before IMPACT, the liver program ran a randomized, placebo-controlled trial in people with MASLD (steatotic liver disease without biopsy-confirmed steatohepatitis), published in JHEP Reports in 2025. The parent study randomized 94 participants to weekly pemvidutide at 1.2 mg, 1.8 mg or 2.4 mg or to placebo, with a subset continuing to 24 weeks of treatment.

At 24 weeks, relative reductions in liver fat content from baseline were 56.3%, 75.2% and 76.4% across the three dose groups, versus 14.0% with placebo. Body weight fell by approximately 6% over the same period, and the authors described the peptide as well tolerated at all doses with low incidences of adverse events. A substantial proportion of treated participants reached liver fat normalization, defined as a hepatic fat fraction of 5% or less.

This trial is useful for two reasons. It is peer-reviewed, and it shows a dose-dependent effect on hepatic fat that is disproportionate to the amount of weight lost, which is the central argument for adding glucagon agonism rather than simply pushing GLP-1 activity higher. Its limitations are equally clear: a small sample, imaging rather than histological endpoints, and a short duration relative to the natural history of liver disease.

On the preclinical side, the published mouse study of ALT-801 in a biopsy-confirmed diet-induced obese model of steatohepatitis compared the dual agonist against semaglutide and elafibranor over 12 weeks of daily dosing. Earlier company-sponsored analyses have also examined effects on pathogenic lipid mediators and on cardiovascular risk markers across the program. Animal and biomarker findings establish mechanism and plausibility; they do not demonstrate clinical benefit, and histology remains the reference standard in MASH.

The reported tolerability profile is dominated by the same gastrointestinal effects seen across the incretin class: nausea, vomiting, diarrhea, constipation and reduced appetite. In IMPACT, adverse events of any kind occurred in 78% and 81% of the two pemvidutide groups versus 67% on placebo, and were described as predominantly mild to moderate and concentrated in roughly the first eight weeks of dosing. Discontinuations attributed to adverse events were low in that trial, reported as 0 of 41 on placebo, 1 of 85 on 1.2 mg and 2 of 86 on 1.8 mg.

Because pemvidutide is given without titration, the early weeks are when gastrointestinal effects would be expected to cluster. That design choice simplifies administration but removes the gradual ramp-up that is used specifically to reduce early nausea with other agents. Readers interested in how these effects behave across the class can read our article on GLP-1 side effects.

The glucagon arm raises additional theoretical considerations that trials have monitored: hepatic glucose output and glycemic control, heart rate, and blood pressure. Reported data so far have been reassuring rather than concerning. In IMPACT, fasting glucose and HbA1c showed no significant change, heart rate was essentially unchanged (a reported change of -0.8 beats per minute on 1.8 mg), and systolic blood pressure decreased by about 4 to 5 mmHg. The sponsor has also reported no imbalance in cardiac adverse events versus placebo in its 48-week dataset.

These findings come from phase 2 trials involving a few hundred participants over 24 to 48 weeks. That is not enough exposure to detect uncommon adverse events, and it says nothing about use in pregnancy, in older adults with frailty, in advanced liver disease, in people with a history of pancreatitis or medullary thyroid carcinoma, or in combination with other glucose-lowering drugs. Long-term safety and cardiovascular outcome data do not yet exist.

Anyone considering any GLP-1-based therapy should discuss it with a physician or pharmacist. Investigational peptides obtained outside a clinical trial carry additional and unquantifiable risks related to identity, purity, sterility and dosing accuracy, and are not appropriate for human use.

Pemvidutide, survodutide (Boehringer Ingelheim) and mazdutide (Innovent Biologics, licensed from Eli Lilly) are all GLP-1/glucagon dual agonists, which makes them conceptually close relatives and clinically quite different. They differ in receptor balance, dose range, titration requirements, geography and how far their programs have advanced in each indication.

Several comparisons are worth noting. Survodutide has the longer histological dataset in MASH, with 48-week biopsy endpoints published in the New England Journal of Medicine in 2024 and a fibrosis signal at that time point. Pemvidutide's IMPACT trial reported a numerically high MASH resolution rate at only 24 weeks, which is a shorter interval than most MASH trials use, but did not show significant fibrosis improvement at that point. Mazdutide is the furthest along commercially, having completed phase 3 obesity trials in China and reached approval there, but its development has been centered on Chinese populations.

No randomized head-to-head trial compares any two of these molecules. Differences in trial duration, fibrosis stage at entry, placebo response, geography and endpoint definitions make cross-trial ranking unreliable, and apparent gaps between percentages in the table above should not be read as differences in efficacy.

As of October 2026, pemvidutide is not approved anywhere. It cannot be prescribed, and it is not legally marketed as a medicine in the United States, the European Union, the United Kingdom or any other major jurisdiction.

Its regulatory position within the development pathway has nonetheless advanced. The FDA granted pemvidutide Fast Track designation for MASH and, separately, Fast Track designation for alcohol use disorder. In January 2026 the sponsor announced that the FDA had granted Breakthrough Therapy designation for MASH on the basis of the 24-week IMPACT data. These designations are procedural: they shorten and intensify the regulatory dialogue, and they do not represent any conclusion about efficacy or safety, nor do they guarantee eventual approval.

The MASH program has moved into phase 3 with the PERFORMA trial in non-cirrhotic MASH. In parallel, a phase 2 trial in alcohol use disorder (RECLAIM) has evaluated once-weekly pemvidutide against placebo over 24 weeks, with endpoints based on heavy drinking days and on phosphatidylethanol, a serum marker of alcohol intake. The sponsor has announced positive topline results from that trial; detailed peer-reviewed data were not yet available at the time of writing. Alcohol-associated liver disease is also listed as a program indication, and obesity development has continued alongside the liver work.

For readers, the practical consequences are straightforward. Pemvidutide is not something that can be legitimately obtained, and the only appropriate route of access is participation in an authorized clinical trial. Material sold online as a research peptide is not manufactured to pharmaceutical standards, is not subject to regulatory oversight for human use, and carries unverifiable risks. Legal status varies by jurisdiction, and possession or import may be restricted where you live.

Medical disclaimer: this guide is educational and does not constitute medical advice, a diagnosis or a dosing recommendation. Pemvidutide is a research compound not approved for human use outside clinical trials. Decisions about obesity, liver disease or alcohol use disorder should be made with a qualified healthcare professional who knows your history.